Ventricular Tachycardia (V-tach or VT) Drug Pipeline Analysis Report 2025

Studies reveal that ventricular tachycardia and ventricular fibrillation are responsible for the majority of cases of sudden cardiac death, accounting for 300,000 deaths annually in the United States. Ventricular tachycardia is also reported to have a strong association with coronary artery disease, with an estimated 15% of the patients affected by coronary artery disease having ventricular tachycardia. The rising burden of cardiovascular conditions is increasing the incidence of ventricular tachycardia, which is expected to fuel the demand for effective therapeutic interventions.

Report Coverage

The Ventricular Tachycardia (V-tach or VT) Drug Pipeline Report by the publisher gives comprehensive insights into ventricular tachycardia (V-tach or VT) drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for ventricular tachycardia (V-tach or VT). The report includes the analysis of over 100 pipeline drugs and 50+ companies. The ventricular tachycardia (V-tach or VT) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from ventricular tachycardia (V-tach or VT).

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing ventricular tachycardia (V-tach or VT) pipeline development activities.

Ventricular Tachycardia (V-tach or VT) Drug Pipeline Outlook

Ventricular tachycardia is defined as a fast, irregular heart rate that occurs in the lower chambers of the heart (ventricles), constituting three or more consecutive heartbeats at a rate of over 100 per minute. The condition is a potentially fatal arrhythmia and is responsible for a substantial percentage of sudden cardiac deaths in the United States. Ischemic heart disease is considered the most common cause of ventricular tachycardia.

Ventricular tachycardia (V-tach or VT) treatment is primarily focused on stabilizing the heart rhythm, preventing recurrence, and managing underlying causes. Antiarrhythmic drugs such as amiodarone, lidocaine, and procainamide are commonly used for preventing episodes of ventricular tachycardia. Advancements in understanding the electrical pathways of the heart are facilitating the identification of novel drug targets, which are likely to positively impact the ventricular tachycardia (V-tach or VT) pipeline landscape in the coming years.

Ventricular Tachycardia (V-tach or VT) - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of ventricular tachycardia (V-tach or VT) drug candidates based on several segmentations including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The ventricular tachycardia (V-tach or VT) therapeutic assessment report covers 50+ drug analyses based on drug classes:

• Antisense Oligonucleotide
• Gene Therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration.

• Oral
• Parenteral
• Others

Ventricular Tachycardia (V-tach or VT) - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III covers a major share of the total clinical trials for ventricular tachycardia (V-tach or VT).

Ventricular Tachycardia (V-tach or VT) - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under ventricular tachycardia (V-tach or VT) pipeline analysis include antisense oligonucleotides, gene therapy, hormones, neuropeptides, oligonucleotides, small molecules, and triglycerides. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for ventricular tachycardia (V-tach or VT).

Ventricular Tachycardia (V-tach or VT) Clinical Trials Therapeutic Assessment - Competitive Dynamics

The ventricular tachycardia (V-tach or VT) drug report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Ventricular Tachycardia (V-tach or VT) clinical trials:

• Cardurion Pharmaceuticals, Inc.
• Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.
• Milestone Pharmaceuticals Inc.
• Varian (a Siemens Healthineers Company)
• Adagio Medical
• Boston Scientific Corporation
• AtaCor Medical, Inc.
• Thermedical, Inc.

Ventricular Tachycardia (V-tach or VT) - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for ventricular tachycardia (V-tach or VT). It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of ventricular tachycardia (V-tach or VT) drug candidates.

Drug: Etripamil NS 70 mg

The objective of this multi-center, double-blind, placebo-controlled study is to assess the safety profile and efficacy of etripamil nasal spray (NS) self-administered by an estimated 500 patients who experience paroxysmal supraventricular tachycardia episodes in an at-home setting. The study is sponsored by Ji Xing Pharmaceuticals (Shanghai) Co., Ltd. and is in Phase III clinical development.

Drug: CRD-4730

Cardurion Pharmaceuticals, Inc. is conducting a Phase 2 study to investigate the pharmacokinetics, safety, tolerability, and pharmacodynamics of the ventricular tachycardia (V-tach or VT) drug candidate CRD-4730 in catecholaminergic polymorphic ventricular tachycardia (CPVT) patients. The study has enrolled around 12 participants and is expected to be completed by September 2026.

Reasons To Buy This Report

The Ventricular Tachycardia (V-tach or VT) Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for ventricular tachycardia (V-tach or VT). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into ventricular tachycardia (V-tach or VT) collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Ventricular Tachycardia (V-tach or VT) - Pipeline Insight Report

• Which companies/institutions are leading the ventricular tachycardia (V-tach or VT) drug development?
• What is the efficacy and safety profile of ventricular tachycardia (V-tach or VT) pipeline drugs?
• Which company is leading the ventricular tachycardia (V-tach or VT) pipeline development activities?
• What is the current ventricular tachycardia (V-tach or VT) commercial assessment?
• What are the opportunities and challenges present in the ventricular tachycardia (V-tach or VT) drug pipeline landscape?
• What is the efficacy and safety profile of ventricular tachycardia (V-tach or VT) pipeline drugs?
• Which company is conducting major trials for ventricular tachycardia (V-tach or VT) drugs?
• Which companies/institutions are involved in ventricular tachycardia (V-tach or VT) collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in ventricular tachycardia (V-tach or VT)?

This product will be delivered within 3-5 business days.